All In Biotech

Drug Trial Radar · NCT07393659

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

197

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Sep 14, 2032

Study completion Sep 14, 2032

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

Conditions

  • HIV Infections

Interventions

  • FostemsavirDrug

    Participants receive oral tablets with the dosages depending on the weight of the participants.

  • Dolutegravir (DTG)/ Lamivudine (3TC)Drug

    Participants receive oral tablets with the dosages depending on the weight of the participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who discontinue the study intervention and the reason for discontinuationTime frame: Throughout the study period (from rollover visit at Day 1 until the end of study/withdrawal visit)
  2. Number of participants with serious adverse events (SAE)Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)
  3. Number of participants with adverse events of special interest (AESI)Time frame: Throughout the study period (from rollover visit at Day 1 until the end of study /withdrawal visit)

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bucharest, Romania · Recruiting

  • GSK Investigational Site

    Gauteng, South Africa · Recruiting

  • GSK Investigational Site

    Johannesburg, South Africa · Recruiting

  • GSK Investigational Site

    Johannesburg, South Africa · Recruiting

  • GSK Investigational Site

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • GSK Investigational Site

    Jouberton, Matlosana, South Africa · Recruiting

  • GSK Investigational Site

    Kampala, Uganda · Recruiting

  • GSK Investigational Site

    Kampala, Uganda · Recruiting

  • GSK Investigational Site

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.